What Is Johnson & Johnson (JNJ) Signaling With Gene Therapy And AI Repurposing?
Johnson & Johnson advanced its gene therapy candidate Botaretigene sparoparvovec for X-linked retinitis pigmentosa in ongoing regulatory and clinical processes. The company expanded drug repurposing programs that use AI tools to reanalyze existing compounds for oncology and rare diseases. Management took a leading role in global collaborations focused on AI-driven compound repurposing.
Read the original →